Видео ютуба по тегу Benevolentai

BenevolentAI – Accelerating Scientific Discovery With AI
BenevolentAI – Accelerating Scientific Discovery With AI
BenevolentAI CEO Dr Joerg Moeller discusses AI's impact on drug discovery
BenevolentAI CEO Dr Joerg Moeller discusses AI's impact on drug discovery
BenevolentAI · AI-Enabled Drug Discovery
BenevolentAI · AI-Enabled Drug Discovery
Can a machine brain cure disease? Ken Mulvany, BenevolentAI
Can a machine brain cure disease? Ken Mulvany, BenevolentAI
Innovation in AI for Target Identification & Drug Discovery, Anne Phelan, CSO BenevolentAI
Innovation in AI for Target Identification & Drug Discovery, Anne Phelan, CSO BenevolentAI
BenevolentAI & AstraZeneca: Fusing AI and Drug Discovery Expertise to Find New Treatments for CKD
BenevolentAI & AstraZeneca: Fusing AI and Drug Discovery Expertise to Find New Treatments for CKD
BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation
BenevolentAI, which uses AI to develop drugs and energy solutions, nabs $115M at $2B valuation
Running on AWS, BenevolentAI Uses its Knowledge Graph to Facilitate New Drug Discovery
Running on AWS, BenevolentAI Uses its Knowledge Graph to Facilitate New Drug Discovery
BenevolentAI’s Innovation Week: pushing the boundaries of AI in drug discovery
BenevolentAI’s Innovation Week: pushing the boundaries of AI in drug discovery
Circl | BenevolentAi Testimonial - Joanna & Yenka
Circl | BenevolentAi Testimonial - Joanna & Yenka
BenevolentAI and AstraZeneca Advance Heart Failure Treatment Discovery
BenevolentAI and AstraZeneca Advance Heart Failure Treatment Discovery
BenevolentAI & AstraZeneca: identifying novel targets for chronic kidney disease
BenevolentAI & AstraZeneca: identifying novel targets for chronic kidney disease
IH 2018 - BenevolentAI, Amir Saffari, SVP of AI
IH 2018 - BenevolentAI, Amir Saffari, SVP of AI
Nuevo Adevinta Meetup: Machine Learning solutions at BenevolentAI and Adevinta Spain
Nuevo Adevinta Meetup: Machine Learning solutions at BenevolentAI and Adevinta Spain
Nicola Richmond, VP of AI, #BenevolentAI on #skillsgaps in #lifesciences
Nicola Richmond, VP of AI, #BenevolentAI on #skillsgaps in #lifesciences
ИИ совершает революцию в разработке лекарств: встречайте R2 Mini от Benevolent AI
ИИ совершает революцию в разработке лекарств: встречайте R2 Mini от Benevolent AI